[1]
|
Kaposztas, Z., Podder, H., Mauiyyedi, S., et al. (2009) Impact of Rituximab Therapy for Treatment of Acute Humoral Rejection. Clinical Transplantation, 23, 63-73. https://doi.org/10.1111/j.1399-0012.2008.00902.x
|
[2]
|
Kolb, H.-J. (2017) Hematopoietic Stem Cell Transplantation and Cellular Therapy. National Library of Medicine, 89, 267-277.
|
[3]
|
Pescovitz, M.D. (2006) Rituximab, an Anti-cd20 Monoclonal Antibody: History and Mechanism of Action. American Journal of Transplantation, 6, 859-866. https://doi.org/10.1111/j.1600-6143.2006.01288.x
|
[4]
|
Morath, C., Beimler, J., Opelz, G., et al. (2012) Living Donor Kidney Transplantation in Crossmatch-Positive Patients Enabled by Peritransplant Immunoadsorption and Anti-CD20 Therapy. Transplant International, 25, 506-513. https://doi.org/10.1111/j.1432-2277.2012.01447.x
|
[5]
|
Xia, R., Qiu, H.Y., Zhang, W.P., et al. (2005) Dynamic Monitoring of Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation by Soluble HLA-I Antigen Detection. Academic Journal of the First Medical College of PLA, 25, 687-690.
|
[6]
|
Okamoto, M., et al. (2006) Rituximab Is Effective for Steroid-Refractory Sclerodermatous Chronic Graft-versus-Host Disease. Transplantation Proceedings, 20, 172-173. https://doi.org/10.1038/sj.leu.2403996
|
[7]
|
Carella, A.M., et al. (2007) Rituximab Is Effective for Extensive Steroid-Refractory Chronic Graft-versus-Host Disease. QJM, 48, 623-624. https://doi.org/10.1080/10428190601094362
|
[8]
|
Zaja, F., et al. (2007) Treatment of Refractory Chronic GVHD with Rituximab: A GITMO Study. Haematologica, 40, 273-277. https://doi.org/10.1038/sj.bmt.1705725
|
[9]
|
Mohty, M., et al. (2008) Rituximab as Salvage Therapy for Refractory Chronic GVHD. Clinical Transplants, 41, 909-911. https://doi.org/10.1038/bmt.2008.12
|
[10]
|
von Bonin, M., et al. (2008) Treatment of Chronic Steroid-Refractory Graft-versus-Host Disease with Low-Dose Rituximab. Transplantation Proceedings, 86, 875-879 https://doi.org/10.1097/TP.0b013e318183f662
|
[11]
|
Clavert, A., et al. (2013) Safety and Efficacy of Rituximab in Steroid-Refractory Chronic GVHD. Human Immunology, 48, 734-736. https://doi.org/10.1038/bmt.2012.203
|
[12]
|
Stasi, R. (2010) Rituximab in Autoimmune Hematologic Diseases: Not Just a Matter of B Cells. Seminars in Hematology, 47, 170-179. https://doi.org/10.1053/j.seminhematol.2010.01.010
|
[13]
|
Larrar, S., Guitton, C., Willem, M., et al. (2006) Severe Hematological Side Effects Following Rituximab Therapy in Children. Haematologica, 91, ECR36.
|
[14]
|
Matthews, D.C. (2003) Rituximab in the Very Young: Benefits in AIHA, at What Risk? Blood, 101, 3761. https://doi.org/10.1182/blood-2003-03-0834
|
[15]
|
Quartier, P., Tournilhac, O., Archimbaud, C., et al. (2003) Enteroviral Meningoencephalitis after Anti-CD20 (Rituximab) Treatment. Clinical Infectious Diseases, 36, e47-e49. https://doi.org/10.1086/345746
|
[16]
|
Zhang, Z.N. and Shen, D. (2007) Diagnosis and Therapeutic Criteria of Hematologic Diseases. 3rd Edition, Science Press, Beijing, 3-70.
|
[17]
|
Zent, C.S., Seereto, C.R., Laplant, B.R., et al. (2008) Direct and Complement Dependent Cytotoxicity in CLL Cells from Patients with High-Risk Early-Intermediate Stage Chronic Lymphocytic Leukemia (CLL) Treated with Alemtuzumab and Rituximab. Leukemia Research, 32, 1849-1856. https://doi.org/10.1016/j.leukres.2008.05.014
|
[18]
|
Klepfish, A., Rachmilewitz, E.A., Kotsianidis, I., et al. (2008) Adding Fresh Frozen Plasma to Rituximab for the Treatment of Patients with Refractory Advanced CLL. QJM, 101, 737. https://doi.org/10.1093/qjmed/hcn085
|
[19]
|
Michael, J.K., Susan, O.B., Maher, A., et al. (2005) Early Results of Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 18, 4079. https://doi.org/10.1200/JCO.2005.12.051
|
[20]
|
William, W., Susan, O.B., Sijin, W., et al. (2005) Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 18, 1070. https://doi.org/10.1200/JCO.2005.12.516
|
[21]
|
Brien, S.M., Kantarjian, H., Thomss, D.A., et al. (2001) Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 19, 2165-2170. https://doi.org/10.1200/JCO.2001.19.8.2165
|
[22]
|
Hainsworth, J.D., Litchy, S., Barrom, J.H., et al. (2003) Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 21, 1746-1751. https://doi.org/10.1200/JCO.2003.09.027
|
[23]
|
Dorner, T. and Lipsky, P.E. (2007) B-Cell Targeting: A Novel Approach to Immune Intervention Today and Tomorrow. Expert Opinion on Biological Therapy, 7, 1287. https://doi.org/10.1517/14712598.7.9.1287
|
[24]
|
Shanafelt, T.D., Madueme, H.I., Wolf, R.C., et al. (2003) Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome. Mayo Clinic Proceedings, 78, 1340. https://doi.org/10.4065/78.11.1340
|
[25]
|
Xu, J. and Qiu, H.Y. (2007) Rituximab Combined with Cyclosporine in the Treatment of Refractory Idiopathic Thrombocytopenic Purpura: A Case Report. Clinical Meta, 22, 1122.
|
[26]
|
Zhou, Z.P. (2006) Clinical Progress of B Cell Elimination Therapy (Meruximab) in ITP. International Journal of Blood Transfusion and Hematology, 29, 495.
|
[27]
|
Satoru, K. (2005) Rituximab Provided Long-Term Remission in a Patient with Refractory Relapsing Thrombotic Thrombocytopenic Purpura. International Journal of Hematology, 81, 433-436. https://doi.org/10.1532/IJH97.04187
|
[28]
|
Sperr, W.R., Lechner, K. and Pabinger, L. (2007) Rituximab for the Treatment of Acquired Antibodies to Factor VIII. Haematologica, 92, 66. https://doi.org/10.3324/haematol.10553
|
[29]
|
Zeiser, R. and Blazar, B.R. (2017) Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. The New England Journal of Medicine, 377, 2565-2579. https://doi.org/10.1056/NEJMra1703472
|
[30]
|
Li, X., et al. (2019) Developing Role of B Cells in the Pathogenesis and Treatment of Chronic GVHD. International Journal of Immunogenetics, 184, 323-336. https://doi.org/10.1111/bjh.15719
|
[31]
|
Galimberti, S., Guerrini, F., Morabito, F., et al. (2003) Quantitative Molecular Evaluation in Autotransplant Programs for Follicular Lymphoma: Efficacy of in Vivo Purging by Rituximab. Bone Marrow Transplantation, 32, 57-63. https://doi.org/10.1038/sj.bmt.1704102
|
[32]
|
Fedoriw, Y., et al. (2012) Bone Marrow B Cell Precursor Number after Allogeneic Stem Cell Transplantation and GVHD Development. Annals of Surgical Treatment and Research, 18, 968-973. https://doi.org/10.1016/j.bbmt.2012.03.005
|
[33]
|
Rehwald, U., Schulz, H., Reiser, M., et al. (2003) Treatment of Relapsed CD20+ Hodgkin Lymphoma with the Monoclonal Antibody Rituximab Is Effective and Well Tolerated: Results of a Phase 2 Trial of the German Hodgkin Lymphoma Study Group. Blood, 101, 420-424. https://doi.org/10.1182/blood.V101.2.420
|
[34]
|
Hochster, H.S., Weller, E., Ryan, T., et al. (2004) Results of E1496: A Phase III Trial of CVP with or without Maintenance Rituximab in Advanced Indolent Lymphoma (NHL). Journal of Clinical Oncology, 22, 6502. https://doi.org/10.1200/jco.2004.22.90140.6502
|
[35]
|
Dorner, T. and Lipsky, P.E. (2007) B-Cell Targeting: A Novel Approach to Immune Intervention Today and Tomorrow. Expert Opinion on Biological Therapy, 7, 1287. https://doi.org/10.1517/14712598.7.9.1287
|
[36]
|
Li, J. and Wang, H.H. (2016) Simple Differential Diagnosis of Hematologic Diseases. People’s Medical Publishing House, Beijing, 3-450. https://doi.org/10.18044/Medinform.201632.450
|
[37]
|
Feucht, H.E., Schneeberger, H., Hillebrand, G., Burkhardt, K., Weiss, M., Reithmuller, G., Land, W. and Albert, E. (1993) Capillary Deposition of C4d Complement Fragment and Early Renal Graft Loss. Kidney International, 43, 1333-1338. https://doi.org/10.1038/ki.1993.187
|
[38]
|
Vieira, C.A., Agarwal, A., Book, B.K., et al. (2004) Rituximab for Reduction of Anti-HLA Antibodies in Patients Awaiting Renal Transplantation: 1. Safety, Pharmacodynamics, and Pharmacokinetics. Transplantation, 77, 542-548. https://doi.org/10.1097/01.TP.0000112934.12622.2B
|
[39]
|
Clifford, D.B., Ances, B., Costello, C., et al. (2011) Rituximab Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. Archives of Neurology, 68, 1156-1162. https://doi.org/10.1001/archneurol.2011.103
|
[40]
|
Genberg, H., Hansson, A.A., Wernerson, L., et al. (2007) Pharmacodynamics of Rituximab in Kidney Transplantation. Transplantation, 84, 33-36. https://doi.org/10.1097/01.tp.0000296122.19026.0f
|
[41]
|
Celik, A., Saglam, F., Cavdar, C., et al. (2008) Successful Therapy with Rituximab of Refractory Acute Humoral Renal Transplant Rejection: A Case Report. Transplantation Proceedings, 40, 302-304. https://doi.org/10.1016/j.transproceed.2007.11.011
|
[42]
|
Tanriover, B., Wright, S.E., Foster, S.V., et al. (2008) High-Dose Intravenous Immunoglobulin and Rituximab Treatment for Antibody-Mediated Rejection after Kidney Transplantation: A Cost Analysis. Transplantation Proceedings, 40, 3393-3396. https://doi.org/10.1016/j.transproceed.2008.08.131
|
[43]
|
Faguer, S., Kamar, N., Guilbeaud-Frugier, C., et al. (2007) Rituximab Therapy for Acute Humoral Rejection after Kidney Transplantation. Transplantation, 83, 1277-1280. https://doi.org/10.1097/01.tp.0000261113.30757.d1
|
[44]
|
Wade, E., Goral, S., Kearns, J., et al. (2006) Experience with Antibody Mediated Rejection in Kidney Allograft Recipients. Clinical Transplants, 10, 439-446.
|